In collaboration with Payame Noor University and Iranian Health Psychology Association

Document Type : Scientific Research

Authors

1 Department of Psychology, Shahid Beheshti University

2 Assistant Professor, Department of Clinical and Health Psychology, Faculty of Psychology and Educational Sciences, Shahid Beheshti University, Tehran, Iran.

3 Postdoctoral Researcher, Spinal Pain Rehabilitation Centre, School of Sport, Exercise and Rehabilitation Sciences, College of Environmental and Life Sciences, University of Birmingham, Birmingham, UK.

4 Assistant Professor, Neurologist, MS Research Center, Neuroscience Research Institute, Tehran University of Medical Sciences, Tehran, Iran

5 Master of clinical psychology Faculty of Psychology and Educational Sciences, Shahid Beheshti University, Tehran, Iran.

10.30473/hpj.2025.71170.6047

Abstract

Objective: This study aimed to explore the role of executive functions in moderating the relationship between medication adherence and depression among individuals with Multiple Sclerosis (MS). MS is a chronic disease that affects the central nervous system, and both cognitive and emotional factors can significantly influence how patients adhere to treatment plans. Medication adherence is crucial for disease management, and depression is a common comorbidity in MS patients, often complicating adherence. Understanding the relationship between depression, cognitive functions, and treatment adherence can help improve therapeutic outcomes. Method: This research was conducted as a descriptive-correlational study, targeting MS patients residing in Tehran. The sample consisted of 229 participants, selected through convenience sampling. These individuals completed three standardized questionnaires: the Beck Depression Inventory (second edition, 2005), the Executive Function Questionnaire by Najafi et al. (2014), and the Morisky Medication Adherence Scale (2008). Data collection was done through a paper-and-pencil survey method. To analyze the data, Pearson's correlation coefficient was used to examine relationships between variables, and stepwise regression analysis was performed to determine if executive functions moderate the relationship between depression and medication adherence. Results: The study found that depressive symptoms were a significant predictor of poor medication adherence in MS patients (p<0.01). This suggests that patients with higher levels of depression are more likely to struggle with adhering to their treatment regimens. Additionally, executive functions such as memory, planning, and social cognition were found to significantly predict medication adherence (p<0.01). These cognitive abilities likely help patients better manage their treatment schedules and follow medical instructions. However, the study did not find evidence supporting the role of executive functions as a moderator in the relationship between depressive symptoms and medication adherence (p>0.01). This indicates that while cognitive abilities and depression are related to medication adherence, executive functions do not appear to change the strength or direction of the relationship between depression and adherence. Conclusion: The findings highlight the importance of both depressive symptoms and executive functions in influencing medication adherence in MS patients. Given that poor medication adherence can lead to worse health outcomes, addressing both cognitive and emotional barriers to treatment is critical. Healthcare providers should consider these factors when designing treatment plans for MS patients. For example, interventions aimed at improving executive functions, such as memory and planning, as well as addressing depression, may be beneficial. By targeting both cognitive and emotional challenges, providers can help patients better adhere to their treatment regimens, which could ultimately improve disease prognosis and quality of life. Furthermore, healthcare teams should be aware of the multifaceted nature of treatment adherence and incorporate psychological and cognitive assessments into routine care to ensure comprehensive support for MS patients. In conclusion, while executive functions may not moderate the relationship between depression and adherence, they are still crucial in predicting adherence, suggesting that an integrated approach to treatment planning is vital for enhancing medication compliance in MS patients.

Keywords

Main Subjects

Ahrari, S., Tooqian Chaharsoughi, N., Basiri Moghaddam, M., Khodadoust, Sh., & Mohtasham, F. (2015). Determining the relationship between depression and adherence to therapeutic regimens in patients with type 2 diabetes referred to 22 Bahman Hospital in Gonabad.DOI: 10.1001/archinte.160.21.3278
Alosaimi, F. D., AlMulhem, A., AlShalan, H., Alqazlan, M., Aldaif, A., Kowgier, M., Balasundaram, J., & Sockalingam, S. (2017). Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis. Patient preference and adherence, 513-518.  DOI: 10.2147/PPA.S129678
Anderson, L. J., Nuckols, T. K., Coles, C., Le, M. M., Schnipper, J. L., Shane, R., Jackevicius, C., Lee, J., Pevnick, J. M., & PHARM-DC Group Choudhry Niteesh K MD, P. D. O. M. D. M. S. C. M. (2020). A systematic overview of systematic reviews evaluating medication adherence interventions. American Journal of Health-System Pharmacy, 77(2), 138-147. DOI: 10.1093/ajhp/zxz284
Arroyo, E., Grau, C., Ramo, C., Parra, J., & Sánchez-Soliño, O. (2010). Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results. Neurología (English Edition), 25(7), 435-442.  PMID: 20964990
Basso, M. R., Shields, I. S., Lowery, N., Ghormley, C., Combs, D., Arnett, P. A., & Johnson, J. (2008). Self-reported executive dysfunction, neuropsychological impairment, and functional outcomes in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 30(8),920-930.DOI: 10.1080/13803390801888733
Beatty, W. W., & Monson, N. (1994). Picture and motor sequencing in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 16(2),165-172. https://doi.org/10.1080/01688639408402627
Bertolin, D. C., Pace, A. E., Cesarino, C. B., Ribeiro, R. d. C. H. M., & Ribeiro, R. M. (2015). Psychological adaptation to and acceptance of type 2 diabetesmellitus. ACTA Paulista de Enfermagem, 28, 440-446. DOI: 10.1590/1982-0194201500074
Boeschoten, R. E., Braamse, A. M., Beekman, A. T., Cuijpers, P., van Oppen, P., Dekker, J., & Uitdehaag, B. M. (2017). Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. Journal of the neurological sciences, 372, 331-341.  Doi: 10.1016/j.jns.2016.11.067
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014). Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology, 83(11), 1022-1024.  doi: 10.1212/WNL.000000000000076
Bruce, J. M., Hancock, L. M., Arnett, P., & Lynch, S. (2010). Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. Journal of behavioral medicine, 33, 219-227. DOI: 10.1007/s10865-010-9247-y
Burkhard, A., Toliver, J., & Rascati, K. (2021). Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of managed care & specialty pharmacy, 27(7), 915-923. DOI: 10.18553/jmcp.2021.27.7.915
Burks, J., Marshall, T. S., & Ye, X. (2017). Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics and outcomes research, 251-260. DOI: 10.2147/CEOR.S130334
Calabrese, P. (2006). Neuropsychology of multiple sclerosis: An overview. Journal of neurology, 253, i10-i15. DOI: 10.1007/s00415-006-1103-1
Cerezo García, M., Martín Plasencia, P., & Aladro Benito, Y. (2015). Alteration profile of executive functions in multiple sclerosis. Acta Neurologica Scandinavica, 131(5), 313-320. DOI: 10.1111/ane.12345
Cerezo García, M., Martín Plasencia, P., Aladro Benito, Y., Balseiro Gómez, J. J., & Rueda Marcos, A. (2009). Executive function and memory in patients with relapsing-remitting multiple sclerosis. Psicothema, 21(3), 416-420. PMID: 19622322
Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of therapy switching. Journal of the neurological sciences, 259(1-2), 104-108. DOI: 10.1016/j.jns.2006.05.075
Cox, D., & Stone, J. (2006). Managing self–injection difficulties in patients with relapsing–remitting multiple sclerosis. Journal of Neuroscience Nursing, 38(3), 167-171. DOI: 10.1097/01376517-200606000-00005
Devonshire, V., Lapierre, Y., Macdonell, R., Ramo‐Tello, C., Patti, F., Fontoura, P., Suchet, L., Hyde, R., Balla, I., & Frohman, E. (2011). The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis. European Journal of Neurology, 18(1), 69-77. DOI: 10.1111/j.1468-1331.2010.03110.x
Diamond, A. (2020). Executive functions. In Handbook of clinical neurology (Vol. 173, pp. 225-240). Elsevier. https://doi.org/10.1016/B978-0-444-64150-2.00020-4
Drew, M., Tippett, L. J., Starkey, N. J., & Isler, R. B. (2008). Executive dysfunction and cognitive impairment in a large community-based sample with Multiple Sclerosis from New Zealand: a descriptive study. Archives of clinical neuropsychology, 23(1), 1-19. DOI: 10.1016/j.acn.2007.09.005
Deyyanti, Mansour, Nejad, M., & Taghaddosi. (2019). Examining medication adherence and its related factors in patients with coronary artery syndrome during the post-discharge period from Beheshti Hospital in Kashan in 2017. Feyz Journal of Kashan University of Medical Sciences, 23(2), 201,208. doi 10.1186/s12955-018-0921-z
Fiest, K., Walker, J., Bernstein, C., Graff, L., Zarychanski, R., Abou-Setta, A., Patten, S., Sareen, J., Bolton, J., & Marriott, J. (2016). Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple sclerosis and related disorders, 5, 12-26. DOI: 10.1016/j.msard.2015.10.004
Foong, J., Rozewicz, L., Quaghebeur, G., Davie, C., Kartsounis, L., Thompson, A., Miller, D., & Ron, M. (1997). Executive function in multiple sclerosis. The role of frontal lobe pathology. Brain: a journal of neurology, 120(1), 15-26. DOI: 10.1093/brain/120.1.15
Godefroy, O., Azouvi, P., Robert, P., Roussel, M., LeGall, D., Meulemans, T., & Group, B. o. t. G. d. R. s. l. E. d. F. E. S. (2010). Dysexecutive syndrome: diagnostic criteria and validation study. Annals of neurology, 68(6), 855-864. DOI: 10.1002/ana.22117
Guzik, A., & Kwolek, A. (2015). Częstość występowania i rozmieszczenie stwardnienia rozsianego w Polsce i na świecie.
Ghashlaq, G., Abadi, Abbas, Raygani, V., Tabrizi, N., Kian, Dalvandi, Mahmoudi, & Hasan. (2015). Determining the criterion validity of the Morisky Medication Adherence Scale in type 2 diabetic patients. Journal of Rehabilitation Nursing Research, 1(3), 24–32. http://ijrn.ir/article-1-98-en.html
Henry, A., Tourbah, A., Camus, G., Deschamps, R., Mailhan, L., Castex, C., Gout, O., & Montreuil, M. (2019). Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support. Multiple sclerosis and related disorders, 27, 46-51. DOI: 10.1016/j.msard.2018.09.039
Horne, R., & Weinman, J. (2020). Predicting treatment adherence: an overview of theoretical models. Adherance to Treatment in Medical Conditions, 25-50.
Husseini, Z., Nejati, V., & Habibi, M. (2019). The Relationship between Poor Executive Functioning and Social Functioning and the Efficacy of Brain Training on Social Functioning. Journal of Rehabilitation Sciences & Research, 6(2), 95-100.
Ivanova, J., Bergman, R., Birnbaum, H., Phillips, A., Stewart, M., & Meletiche, D. (2012). Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Journal of medical economics, 15(3), 601-609. DOI: 10.3111/13696998.2012.667027
Jackson-Koku, G. (2016). Beck depression inventory. Occupational medicine, 66(2), 174-175. DOI: 10.1093/occmed/kqv087
Khalili, F., Eslami, A. A., Farajzadegan, Z., & Hasan Zadeh, A. (2011). Investigating the relationship between some psychosocial factors and adherence behaviors to treatment in hemodialysis patients in Isfahan: A conceptual framework based on the social-cognitive theory. http://unmf.umsu.ac.ir/article-1-3071-en.html
Kołtuniuk, A., & Rosińczuk, J. (2021). The levels of depression, anxiety, acceptance of illness, and medication adherence in patients with multiple sclerosis-descriptive and correlational study. International journal of medical sciences, 18(1), 216. DOI: 10.7150/ijms.51172
Lasa, L., Ayuso-Mateos, J. L., Vázquez-Barquero, J. L., Dıez-Manrique, F., & Dowrick, C. F. (2000). The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis. Journal of affective disorders, 57(1-3), 261-265. DOI: 10.1016/s0165-0327(99)00088-9
Lunde, H. M. B., Assmus, J., Myhr, K.-M., Bø, L., & Grytten, N. (2017). Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. Journal of Neurology, Neurosurgery & Psychiatry, 88(8), 621-625. DOI: 10.1136/jnnp-2016-315238
Lovaei, P., Moradi, A., Taher, M., & Mikaeili, N. (2022). The effectiveness of memory-specificity training on emotion regulation and treatment adherence in cancer patients. Clinical Psychology, 14(4), 89–105. https://doi.org/10.22075/jcp.2022.26219.2388
Marrie, R. A., Reingold, S., Cohen, J., Stuve, O., Trojano, M., Sorensen, P. S., Cutter, G., & Reider, N. (2015). The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Multiple Sclerosis Journal, 21(3), 305-317.   
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: a review. Jama, 325(8), 765-779. DOI: 10.1001/jama.2020.26858
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013). Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. Journal of managed care pharmacy, 19(1 Supp A), S24-S40.DOI: 10.18553/jmcp.2013.19.s1.S24
Niroomand, Dehnavi, R., Far, A., & Masoud. (2022). Effectiveness of cognitive rehabilitation using Captain Log software on executive functions in patients with multiple sclerosis. Neuropsychology, 8(29), 73–82. https://doi.org/10.30473/clpsy.2021.60525.1618
Omranifard, V., Ebrahimi, A., Basti, T., Sharabafchi, M., Sajadiyeh, Sh., & Mortazavi, M. (2017). Investigating the relationship between treatment adherence and depression, anxiety, and coping strategies in kidney transplant patients. Journal of Isfahan Medical School, 34(409), 1430–1438. https://jims.mui.ac.i/article_15106_a252b52e7817e7462d1874e44754cfa6.pdf
Oliveira-Filho, A. D., Barreto-Filho, J. A., Neves, S. J. F., & Lyra Junior, D. P. d. (2012). Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control. Arquivos brasileiros de cardiologia, 99, 649-658. DOI: 10.1590/s0066-782x2012005000053
Peyser, J. M., Edwards, K. R., Poser, C. M., & Filskov, S. B. (1980).  Cognitive function in patients with multiple sclerosis. Archives of neurology, 37(9), 577-579.DOI: 10.1001/archneur.1980.00500580073013
Pham, T., Jetté, N., Bulloch, A. G., Burton, J. M., Wiebe, S., & Patten, S. B. (2018). The prevalence of anxiety and associated factors in persons with multiple sclerosis. Multiple sclerosis and related disorders, 19, 35-39. DOI:10.1016/j.msard.2017.11.003
Rao, S. M. (1995). Neuropsychology of multiple sclerosis. Current opinion in Neurology, 8(3), 216-220.DOI: 10.1097/00019052-199506000-00010
Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41(5), 685-691.DOI: 10.1212/wnl.41.5.685
Remington, G., Rodriguez, Y., Logan, D., Williamson, C., & Treadaway, K. (2013). Facilitating medication adherence in patients with multiple sclerosis. International journal of MS care, 15(1), 36-45.DOI: 10.7224/1537-2073.2011-038
Río, J., Porcel, J., Téllez, N., Sánchez-Betancourt, A., Tintoré, M. a., Arévalo, M. J., Nos, C., & Montalban, X. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 11(3), 306-309. DOI: 10.1191/1352458505ms1173oa
Sakaki, S., Naderi, F., & Hafezi, F. (2023). The causal relationship of depression with health-related quality of life through the mediating chain of chronic fatigue and treatment adherence in women with uterine cancer. Applied Family Therapy, 4(1), 512–533. https://doi.org/10.22034/aftj.2023.336847.1520
Shafer, A. B. (2006). Meta‐analysis of the factor structures of four depression questionnaires: Beck, CES‐D, Hamilton, and Zung. Journal of clinical psychology, 62(1), 123-146.DOI: 10.1002/jclp.20213
Steinberg, S. C., Faris, R. J., Chang, C. F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clinical drug investigation, 30, 89-100.DOI: 10.2165/11533330-000000000-00000
Summers, M., Swanton, J., Fernando, K., Dalton, C., Miller, D., Cipolotti, L., & Ron, M. (2008). Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. Journal of Neurology, Neurosurgery & Psychiatry, 79(8), 955-958.   DOI: 10.1136/jnnp.2007.138685
Tan, X., Patel, I., & Chang, J. (2014). Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8). INNOVATIONS in pharmacy, 5(3), 5.DOI: https://doi.org/10.24926/iip.v5i3.347